These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8633984)

  • 21. Criteria for use of colfosceril (Exosurf) in neonates.
    Bhatt-Mehta V; Schumacher RE
    Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of exogenous surfactant in acute lung injury.
    Lewis JF; Brackenbury A
    Crit Care Med; 2003 Apr; 31(4 Suppl):S324-8. PubMed ID: 12682460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome.
    Weg JG; Balk RA; Tharratt RS; Jenkinson SG; Shah JB; Zaccardelli D; Horton J; Pattishall EN
    JAMA; 1994 Nov; 272(18):1433-8. PubMed ID: 7933425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome.
    Seppänen M; Kääpä P; Kero P
    Am J Perinatol; 1994 Nov; 11(6):382-5. PubMed ID: 7857426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exogenous surfactants in a piglet model of acute respiratory distress syndrome.
    Sood SL; Balaraman V; Finn KC; Britton B; Uyehara CF; Easa D
    Am J Respir Crit Care Med; 1996 Feb; 153(2):820-8. PubMed ID: 8564138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic vs human surfactants in the treatment of respiratory distress syndrome: radiographic findings.
    Levine D; Edwards DK; Merritt TA
    AJR Am J Roentgenol; 1991 Aug; 157(2):371-4. PubMed ID: 1853824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artificial surfactant attenuates hyperoxic lung injury in primates. II. Morphometric analysis.
    Piantadosi CA; Fracica PJ; Duhaylongsod FG; Huang YC; Welty-Wolf KE; Crapo JD; Young SL
    J Appl Physiol (1985); 1995 May; 78(5):1823-31. PubMed ID: 7649918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surfactant therapy in respiratory distress syndrome--the first local experience.
    Lim NL; Nordin MM; Cheah IG
    Med J Malaysia; 1994 Mar; 49(1):4-11. PubMed ID: 8057989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of nitric oxide production by lung surfactant in alveolar macrophages.
    Kalina M; Blau H; Riklis S; Hoffman V
    Adv Exp Med Biol; 2000; 479():37-48. PubMed ID: 10897408
    [No Abstract]   [Full Text] [Related]  

  • 31. Status report: inhaled nitric oxide in persistent pulmonary hypertension/hypoxic respiratory failure of neonate.
    Cook LN
    Przegl Lek; 2002; 59 Suppl 1():10-3. PubMed ID: 12108054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung function in prematurely delivered rabbits treated with a synthetic surfactant.
    Tooley WH; Clements JA; Muramatsu K; Brown CL; Schlueter MA
    Am Rev Respir Dis; 1987 Sep; 136(3):651-6. PubMed ID: 3307569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
    Sehgal SS; Ewing CK; Richards T; Taeusch HW
    J Natl Med Assoc; 1994 Jan; 86(1):46-52. PubMed ID: 8151722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of institutional differences on study of surfactant in two centers.
    Etches PC; Peliowski A; Finer NN; Tierney AJ
    J Pediatr; 1991 Jul; 119(1 Pt 1):162-3. PubMed ID: 2066853
    [No Abstract]   [Full Text] [Related]  

  • 37. [Surfactant-BL and inhaled nitric oxide in acute respiratory distress syndrome in cardiac surgical patients].
    Kozlov IA; Poptsov VN
    Anesteziol Reanimatol; 2005; (6):38-41. PubMed ID: 16499105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs.
    Cummings JJ; Holm BA; Hudak ML; Hudak BB; Ferguson WH; Egan EA
    Am Rev Respir Dis; 1992 May; 145(5):999-1004. PubMed ID: 1586078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of aerosolized artificial surfactant on repeated oleic acid injury in sheep.
    Zelter M; Escudier BJ; Hoeffel JM; Murray JF
    Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):1014-9. PubMed ID: 2327634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.